There are 2867 resources available
484P - CHARIOT trial (cohort A2): A phase I dose-escalation study combining the ATR inhibitor berzosertib with cisplatin and capecitabine
Presenter: Salma El Badri
Session: Poster session 13
485P - Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials
Presenter: Natalie Ngoi
Session: Poster session 13
486P - AK130, a first-in-class Fc-mutant anti-TIGIT antibody fused with TGF-βRII protein, elicits potent anti-tumor efficacy in pre-clinical studies
Presenter: Jing Min
Session: Poster session 13
487P - Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
Presenter: Christoph Heilig
Session: Poster session 13
488P - Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)
Presenter: Michael Schweizer
Session: Poster session 13
489P - Analysis of 3-dimensional volumetric distribution and dispersion of the radioenhancer NBTXR3 in various solid malignancies
Presenter: Thierry de Baere
Session: Poster session 13
490P - Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
Presenter: Antoine Italiano
Session: Poster session 13
491TiP - A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors
Presenter: Timothy Yap
Session: Poster session 13
492TiP - A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion
Presenter: Melissa Johnson
Session: Poster session 13
493TiP - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER-3 antibody) in patients with advanced HER3-positive solid tumours
Presenter: Johann de Bono
Session: Poster session 13